At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT® (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

Sun Pharma reported updated results from 205 patients across three advanced cutaneous squamous cell carcinoma cohorts treated with UNLOXCYT (cosibelimab): objective response rates were 44.4%–53.1%, with complete response rates of 16.7%–34.4%. Among responders, estimated response persistence at two years ranged from 68.6% to 81.8%; grade 3 immune-related adverse events occurred in 2.9%, with no grade 4 events or deaths attributed to these events. The data are an update from a pivotal study of a drug already approved in the U.S.; the company plans to present them at ESMO on October 24, 2026.

Analysis

The investable signal is durability, not a clear efficacy step-up: overall response rates were broadly stable, while longer follow-up added complete responses. That may support clinician confidence and access discussions, but a single-arm dataset cannot establish an advantage over incumbent PD-1 options such as cemiplimab or pembrolizumab. Nor does the claimed mechanism or low rate of high-grade immune events prove superior tolerability without comparative data.

The locally advanced cohort’s long median PFS is potentially commercially relevant, but it should not be extrapolated to metastatic patients: the metastatic cohorts show much shorter median PFS, and the groups differ in disease setting and regimen. The 24-month response estimates apply to responders, not all treated patients. These distinctions matter when translating poster data into addressable patients, treatment duration, and revenue.

Near term, the ESMO presentation can generate attention, but likely has limited read-through to consolidated Sun Pharma absent sales, launch trajectory, or guidance evidence; the product is one asset within a diversified company. Over 1–3 months, watch for market-access expansion and independently verifiable uptake. Over 6–18 months, competition and real-world persistence will determine whether durability converts into share. Falsifiers include weaker real-world treatment persistence, restrictive access, or evidence that response durability does not translate into sustained disease control. The contrarian point: the high complete-response figures may sound like a step-change, but unchanged ORR and responder-only durability estimates make that interpretation premature.

Key Decisions for Investors

• No directional trade on this release alone. Treat it as a modest clinical de-risking signal, not evidence of a material near-term earnings revision for Sun Pharma.
• Watch the ESMO presentation and subsequent Sun Pharma disclosures for cohort-level follow-up, treatment discontinuation, adverse-event detail, and product sales or access data; these are needed to assess commercial conversion.
• For a potential relative-value view, monitor whether UNLOXCYT gains share against established PD-1 treatments in advanced CSCC. Consider exposure only if uptake evidence emerges; the current release does not support a defensible entry level or quantified risk/reward.
• Reassess the thesis if comparative or real-world data show materially weaker durability or tolerability, or if access constraints prevent the clinical profile from translating into treatment adoption.